Q1 Report Reveals Going Concern, Nasdaq Delisting Risk, and Plan for Massive Share Authorization
BRTX is trading near its 52-week low of $0.174 (13% above the low) on light trading volume (0.1× avg).
Summary
BioRestorative Therapies' Q1 report details a going concern warning, Nasdaq delisting risk, and a board-approved plan to increase authorized shares to 1.5 billion, signaling significant future dilution despite a recent capital raise and improved net loss.
Key Events · Financing and Capital Events · BRTX
-
Going Concern Warning Reiterated
The company continues to express substantial doubt about its ability to continue as a going concern for at least the next twelve months, citing anticipated net losses and negative cash flows from operations.
-
Nasdaq Delisting Notice Received
On March 26, 2026, BioRestorative Therapies received a notice from Nasdaq for non-compliance with the minimum $1.00 bid price rule, with a compliance period until September 22, 2026. The company is considering a reverse stock split.
-
Board Approves Massive Increase in Authorized Shares
On April 2, 2026, the Board of Directors approved an increase in authorized common stock from 75 million to 1.5 billion shares, subject to shareholder approval. This represents a potential dilution of over 5800% based on current outstanding shares.
-
Successful Public Offering Completed
In February 2026, the company completed a public offering, raising approximately $4.4 million in net proceeds from the sale of common stock and pre-funded warrants. The offering price was $0.35 per unit.
Analysis · BRTX · Industrial Applications And Services
This quarterly report highlights severe financial distress, including a 'going concern' warning and a Nasdaq delisting notice due to the stock trading below $1.00. While the company successfully raised $4.4 million in a recent offering and improved its net loss, these positives are overshadowed by the fundamental risks. The board's approval to increase authorized shares to 1.5 billion (from 75 million) signals an intent for substantial future dilution, which is critical for a company with a market cap of only $4.8 million and current outstanding shares of 25.5 million. This move, if approved by shareholders, would allow for over 5800% potential dilution, indicating a desperate need for capital that could severely impact existing shareholders.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 42.2% of the 325 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BRTX was trading at $0.20 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.8M. The 52-week trading range was $0.17 to $2.05. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.